← Back to Treatments
🏅 FDA Orphan Designation

MYCAPSSA (formerly Octreolin)

octreotide (oral)

Manufacturer: Chiesi USA, Inc.

Indicated for:
Fourth branchial cleft anomalyOrphan

FDA-Approved Indications (1)

Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Indications & Usage

Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.